angio_8k.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
__________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 2, 2009
AngioDynamics,
Inc.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
000-50761
|
11-3146460
|
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
| |
603
Queensbury Avenue, Queensbury, New York
|
12804 |
| |
(Address
of Principal Executive Offices)
|
(Zip
Code) |
|
|
|
(518)
798-1215
|
|
(Registrant’s
telephone number, including area
code)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2 (b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4 (c))
|
Item
2.02 – Results of
Operations and Financial Condition.
On
April 2, 2009, AngioDynamics, Inc. (the “Company”) issued a press release
announcing financial results for the fiscal third quarter ended February 28,
2009.
The
information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1)
shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in
such a filing.
Forward-Looking
Statements
This document and its attachments
include “forward-looking statements” intended to qualify for the safe harbor
from liability established by the Private Securities Litigation Reform Act of
1995. Investors can identify these statements by the fact that they do not
relate strictly to historical or current facts. These statements contain words
such as “expect,” “reaffirm,” “anticipate,” “plan,” “believe,” “estimate,”
“may,” “will,” “predict,” “project,” “might,” “intend,” “potential,” “could,”
“would,” “should,” “estimate,” “seek,” “continue,” “pursue,” or “our future
success depends,” or the negative or other variations thereof or comparable
terminology, are intended to identify such forward-looking statements. In
particular, they include statements relating to, among other things, future
actions, strategies, future performance and future financial results of the
Company. These forward-looking statements are based on current
expectations and projections about future events.
Investors are cautioned that
forward-looking statements are not guarantees of future performance or results
and involve risks and uncertainties that cannot be predicted or quantified and,
consequently, the actual performance or results of the Company may differ
materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, but are not limited
to, the factors described from time to time in the Company's reports filed with
the SEC, including the Company's Form 10-K for the fiscal year ended May 31,
2008, financial community and rating agency perceptions of the Company; the
effects of economic, credit and capital market conditions on the economy in
general, and on medical device companies in particular; domestic and foreign
health care reforms and governmental laws and regulations; third-party relations
and approvals, technological advances and patents attained by competitors; and
challenges inherent in new product development, including obtaining regulatory
approvals. In addition to the matters described above, the ability of
the Company to develop its products, future actions by the FDA or other
regulatory agencies, results of pending or future clinical trials, the outcome
of pending patent litigation, overall economic conditions, general market
conditions, market acceptance, foreign currency exchange rate fluctuations, and
the effects on pricing from group purchasing organizations and competition
and the ability of the
Company to integrate purchased businesses, may affect the actual results
achieved by the Company.
Any
forward-looking statements are made pursuant to the Private Securities
Litigation Reform Act of 1995 and, as such, speak only as of the date made. The
Company
disclaims any obligation to update the forward-looking statements. Investors are
cautioned not to place undue reliance on these forward-looking statements which
speak only as of the date stated, or if no date is stated, as of the date of
this document.
Item
9.01 – Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press
Release dated April 2, 2009.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
ANGIODYNAMICS,
INC.
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
|
Date:
April 2, 2009
|
By:
|
|
/s/
D. Joseph Gersuk
|
|
|
|
|
D.
Joseph Gersuk
|
|
|
|
|
Chief
Financial Officer
|
|
|
|
|
|
EXHIBIT
INDEX
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press
Release dated April 2, 2009.
|